Juniper Publishers-Journal of Diabetes Obesity Journal

Juniper Publishers-Open Access Journal of Current Research in Diabetes & Obesity Journal     Introduction Bariatric surgery has different types and the most common restrive type of bariatric is Laparoscopic Sleeve gastrectomy [1-4]. The most common place of leak after sleeve gastrectomy is at the esophageal-gastric junction, contained leaks are usually treated by coated self-expending stents, Fibrin sealing glues, coils, percutaneous pigtil drainage [5,6]. In some patients chronic fistulas need total gastrectomy [7]. The technique of laparoscopic sleeve gastrectomy has been standarized and some controversies exist regarding the sleeve volume, coverage of the staple line, bougie used to size the sleeve, extention of the antral resection and so forth [1,2]. In our LGS procedure, the bougie is 36 F in diameter, the antrum is resected 4cm from pylorus using 1st green 45 mm and than 5 blue 60mm long cartridges sequentially. We also enforse the stapler li

CURRENT RESEARCH IN DIABETES & OBESITY JOURNAL JUNIPER PUBLISHER   Abstract Cardiovascular disease (CV) is the leading cause of morbidity and mortality in patients with type 2 diabetes. Glucagon-like peptide-1 receptor agonists are new agents that are very promising because they affect many cardiovascular risk factors, apart from improving the glycemic control. Based on the published LEADER and SUSTAIN-6 trials liraglutide and semaglutide have shown cardiovascular benefit and could be reasonable options as second line agents for patients with CV disease. Lixisenatide have been evaluated in one CV safety trial and has neutral effects on CV outcomes. Individuals without CV disease can be treated with any of the other classes of anti-diabetic medication. However, in patients with established CV disease medications with proven CV benefit should be preferred. Keywords: Cardiovascular disease; Type 2 diabetes mellitus; Glucagon-like peptide-1 receptor agonists